​

Funding Round

Series A - Allogene Therapeutics

Series A - Allogene Therapeutics

Investment Firm

Overview

Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.

Announced Date

Apr 19, 2018

Funding Type

Series A

Highlights

N/A

Location

N/A

Social

N/A

Investor Lead

TPG

TPG

TPG is a debt and early_stage_venture and late_stage_venture and post_ipo and seed firm.

Participant Investors

5

Investor Name
Participant InvestorTwo River
Participant InvestorBellco Capital
Participant InvestorPfizer
Participant InvestorTPG
Participant InvestorGilead Sciences

Round Details and Background

Allogene Therapeutics raised $411770409 on 2018-04-19 in Series A

Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.

Company Funding History

5

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Sep 07, 2018
Convertible Note - Allogene Therapeutics
9-120.0M
Sep 06, 2018
Convertible Note - Allogene Therapeutics
-120.0M
Nov 01, 2019
Post-IPO Equity - Allogene Therapeutics
-250.0M
May 13, 2024
Post-IPO Equity - Allogene Therapeutics
-110.0M

Recent Activity

There is no recent news or activity for this profile.